Title:
生物活性マクロライド、組成物、及びそれらの使用
Document Type and Number:
Japanese Patent JP4980542
Kind Code:
B2
Abstract:
The present invention provides a compound of the formula (I) or (II), wherein R1 is H, alkyl, alkenyl or aryl, R2 is H, alkyl or aryl, R3 is H, a alkyl, alkenyl or aryl, R4 and R4-R8 are independently R10, C(O)R10 or SO2R10, wherein R10 is H, alkyl, alkenyl or aryl, and R9 is R9a, C(O)R9a or SO2R9a, wherein R9a is H, alkyl, alkenyl or aryl. R9a can be unsubstituted or substituted with one or more oxo(═O), OR9b, OC(O)R9b, OSO2R9b, NHR9b, NHC(O)R9b and NHSO2R9b groups. R9b is H, alkyl, alkenyl, or aryl. R9b can be unsubstituted or substituted with one or more groups such as oxo(═O), OR9c, CO2R9c, CO2R9c and OC(O)R9c. R9c is H, or a unsubstituted or substituted alkyl, alkenyl or aryl. The present invention further provides a composition comprising at least one compound of the present invention and a pharmaceutically acceptable carrier, alone or in combination with at least one additional active agent. The present invention further provides a method of treating a condition treatable by the inhibition of vacuolar-type (H+)-ATPase and a method of treating cancer.
Inventors:
Boyd, Michael, Earl.
Gustavson, Kirk, Earl.
Cantrell, Charles, Elle.
Gustavson, Kirk, Earl.
Cantrell, Charles, Elle.
Application Number:
JP2002514137A
Publication Date:
July 18, 2012
Filing Date:
July 24, 2001
Export Citation:
Assignee:
THE UNITED STATES OF AMERICA
International Classes:
C07D498/08; A61K31/395; A61P13/02; A61P15/08; A61P19/10; A61P25/28; A61P27/06; A61P35/00; A61P43/00
Foreign References:
| WO1999005136A1 |
Other References:
S GAGLIARDT et al,Synthesis and Structure-activity Relationships of Bafllomycin A1 Derivatives as Inhibitors of Vacuolar H+-ATPase,Journal of Medicinal Chemistry,1998年,41(11),1883-1893頁
Nigel B. Perry, et al.,Natural Product Letters,1998年,11(4),305-312頁
Michael R. Boyd, et al.,Drug Development Research,1995年,34,91-109頁
Nigel B. Perry, et al.,Natural Product Letters,1998年,11(4),305-312頁
Michael R. Boyd, et al.,Drug Development Research,1995年,34,91-109頁
Attorney, Agent or Firm:
Takashima Ichi